What question did this study set out to answer?

To assess the relationship between hip osteoarthritis and inflammatory arthritis resulting from immune checkpoint inhibitor treatment.

April 17, 2026The Journal of Rheumatology0 citations

View Full Paper

Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis

RFRebecca FitzpatrickJohns Hopkins University SDShadpour Demehri JMJoseph Murray

Key Points

To assess the relationship between hip osteoarthritis and inflammatory arthritis resulting from immune checkpoint inhibitor treatment.
Correction of previously published reference
Review of predictive factors for inflammatory arthritis
Analysis of adverse events related to immune checkpoint inhibitors
Identification of hip osteoarthritis as a relevant risk factor for inflammatory arthritis
Reference to key predictors of rheumatic adverse events has been confirmed

Abstract

J Rheumatol 2026; doi: 10.3899/jrheum.2025-0808 In the originally published online version of this article, reference 8 was missing from the list of references. The missing reference has now been added: "8. Cunningham-Bussel A, Wang J, Prisco LC, et al. Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer. Arthritis Rheumatol 2022;74:527-40." This correction applies only to the February 1 2026 First Release. The complete list of references appears in the print and online issues.

Ask AI

Helpful

Bookmark

View Full Paper

Ask AI

Helpful

Bookmark

View Full Paper

Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis

Key Points

Abstract

Cite This Study

Also Consider

Also Consider